New HIV drugs show promise in early studies.

Focuses on drugs that appear to be potent against HIV, including strains that are resistant, according to research presented at the 9th Annual Conference on Retroviruses and Opportunistic Infections, which was held in Seattle, Washington in February 2002. Mention of anti-HIV drugs that are entry inhibitors and integrase inhibitors.; Discussion of non-nucleoside reverse transcriptase inhibitors (NNRTI) and of TMC 125, a drug developed by Tibotec-Virco in Belgium.